The U.S. Department of Justice filed a complaint under the False Claims Act against Regeneron Pharmaceuticals, according to a press release.
The company is alleged to have “fraudulently inflated Medicare reimbursement rates for Eylea by submitting false average sales price reports to the Centers for Medicare and Medicaid Services.”
According to the release, Regeneron did not report price concessions, which took the form of credit card processing fees that were paid to specialty drug distributors. The company allegedly paid these fees “so that distributors would accept credit